Search results for "antibody"
Article
Maximizing the Effectiveness of Upstream Bioprocessing Through the Combination of Lab Informatics and Instrumentation
With the exception of a few “blockbuster” monoclonal antibody products, which are better suited to large-scale stainless-steel bioreactor production, most biopharmaceutical companies are now increasin…
Article
Securing Today’s Biomanufacturing Supply Chain Using Transformative Supply
Today, biologics represent a $250 billion industry, which is two times what it was worth only 10 years ago. Though monoclonal antibodies are expected to continue dominating the market, a more divers…
Article
New Therapies Present Scaling Challenges
However, differences in manufacturing cycles for emerging therapies, compared with that of the traditional monoclonal antibody (mAb) therapeutic, calls for different strategies to increase production.…
Article
Methods Accelerate Biosimilar Analysis
Mirror image of peptide maps of reduced/alkylated and endo-Lys C digested monoclonal antibody product lots (Upper: Innovator product; Lower: Biosimilar product).
Such a quantitative approach, i…
Article
Tools and Processes for Mature and Emerging Therapies
New technologies and thought trends provide innovative biomanufacturing approaches for a range of therapies.
By Rita Peters
Conference sessions and new technology introductions at recent t…
Article
Design Considerations for a Commercial Cell and Gene Therapy Facility
Different from mAbs
Considering the differences between monoclonal antibody (mAb) production and cell/gene therapy production is also important when establishing a cell/gene therapy facility. Al…
Article
The Outlook for CMO Outsourcing in 2019
…n terms of manufacturing novel products, including antibodies with novel core structures/backbones, antibody-drug conjugates (ADCs), cellular therapies, gene therapies, RNAi, pegylated proteins, and …
Article
A Plastic Pipeline for Commercial Bioprocessing?
A Plastic Pipeline for Commercial Bioprocessing?
The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.
By Rita C. Peters
…
Article
State of the Biopharmaceutical Industry: Lessons from 2018 Survey Data
Survey data show that the lowest costs currently being attained with commercial scale recombinant protein/antibody manufacturing are now in the $100/gram range, with a few of the very largest faciliti…
Article
Integrated Semi-Continuous Process for mAb Production
A complete process for the production of a biopharmaceutical consists of a great number of distinct unit operations, for example, cell culture, filtration, and chromatography. Linking these differen…